AstraZeneca Highlights P-III (SERENA-6) Trial Data on Camizestrant Combination for ESR1 Mutated Advanced Breast Cancer at ASCO’26

Why It Matters

The results position camizestrant as a potential new standard for ESR1‑mutated breast cancer, offering longer disease control and a biomarker‑driven advantage that could accelerate regulatory approvals and reshape treatment algorithms.

Key Takeaways

• Camizestrant combo cut median PFS to 16.8 mo vs 9.2 mo.
• 24‑month PFS rate 34.9% vs 14.2% with AI combo.
• Week‑8 ctDNA fell 99%; 51% of patients cleared.
• Therapy delayed chemo/ADC start by ~4 months, improving QoL.

Pulse Analysis

The emergence of ESR1 mutations has long challenged endocrine therapy for hormone‑receptor‑positive breast cancer, driving resistance to aromatase inhibitors and prompting the development of oral selective estrogen receptor degraders (SERDs). Camizestrant, AstraZeneca’s next‑generation SERD, is designed to bind and degrade mutant estrogen receptors, restoring sensitivity to downstream CDK4/6 inhibition. By targeting the molecular driver of resistance, camizestrant offers a mechanistic advantage over traditional AI‑based regimens, aligning with a broader industry shift toward precision‑focused endocrine strategies.

In the SERENA‑6 trial, 157 patients received camizestrant plus a CDK4/6 inhibitor, while 158 received an AI plus the same CDK4/6 blocker. The camizestrant arm delivered a median PFS of 16.8 months—nearly double the 9.2‑month benchmark of the AI arm—and a 24‑month PFS rate of 34.9% versus 14.2%. Notably, ctDNA monitoring showed a 99% median reduction by week 8, with half of the participants achieving complete ctDNA clearance, a signal that correlated with improved overall survival. The regimen also extended the interval before patients required chemotherapy or antibody‑drug conjugates by about four months, translating into better quality‑of‑life scores.

These data arrive as the breast‑cancer market anticipates several oral SERDs to seek approval in the United States, Europe, and Japan. Camizestrant’s compelling efficacy, biomarker‑driven response, and patient‑centric benefits could secure a first‑to‑market advantage, pressuring competitors to accelerate their pipelines. Moreover, the trial’s robust ctDNA findings may set a new standard for integrating liquid‑biopsy endpoints into oncology trials, offering clinicians an early readout of treatment effectiveness and informing personalized therapeutic decisions.